SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.
- We are grateful for their support in our drive to bring the benefits of SAB-142 to T1D patients in need.
- A replay of Mr. Reich’s presentation will be archived on the SAB Biotherapeutics website for up to one year.
- SAB Biotherapeutics held cash and equivalents of $56.6 million at December 31, 2023, compared to $15.0 million at December 31, 2022.
- SAB reported a net loss of $42.2 million and $18.7 million for the years ended December 31, 2023 and December 31, 2022 respectively.